NCT07310420 2026-03-11
A Trial to Evaluate Ovarian Suppression Following Subcutaneous ZOLADEX 10.8 mg in Premenopausal Women With HR+, HER2- Advanced Breast Cancer
TerSera Therapeutics LLC
Phase 1 Not yet recruiting
Clinical Trials
6 trialsNCT05870579 2025-08-21
[177Lu]Lu-NeoB in Combination With Ribociclib and Fulvestrant in Participants With ER+, HER2- and GRPR+ Advanced Breast Cancer
Novartis
Phase 1 Recruiting
NCT02333370 2023-06-08
A Phase Ib Dose Escalation Study of the Combination of LEE011 With Letrozole and Dose Expansion of LEE011 With Hormonal Therapy for the Treatment of Pre-(With Goserelin) and Postmenopausal Women With Hormone Receptor Positive, HER2-negative, Advanced Breast Cancer
Novartis
Phase 1 Completed
NCT05140512 2023-05-16
Pharmacokinetics, Pharmacodynamics and Safety of LY01005 in Patients With Prostate Cancer Compared to ZOLADEX®
Luye Pharma Group Ltd.
Phase 1 Completed
NCT05856630 2023-05-12
Pharmacokinetics Pharmacodynamics and Safety of LY01022 in Patients With Prostate Cancer Compared With Zoladex® 10.8mg
Luye Pharma Group Ltd.
Phase 1 Unknown
NCT03450109 2019-01-07
A Study to Assess LY01005 Versus Goserelin Comparator (ZOLADEX®) in Patients With Prostate Cancer
Luye Pharma Group Ltd.
Phase 1 Completed